QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use

SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of innovative in vitro diagnostic technologies, is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs.

The QUICKVUE Influenza + SARS Test is designed to deliver  rapid, simultaneous detection and differentiation of influenza A, influenza B and SARS-CoV-2 antigens  from a single patient sample, providing results in as fast as  10 minutes. This capability can help clinicians distinguish between COVID-19 and seasonal flu infections, which present similar symptoms, enabling timely treatment decisions and improved patient outcomes.

Key Features and Benefits:

• Triple Detection Capability : Differentiates influenza A/B and COVID-19 in one test.
• Fast Results : Clear results available in as fast as 10 minutes at the point of care.
• Professional Use : Designed for CLIA-waived and moderate/high-complexity lab settings.
• Efficient Workflow : Easy-to-collect nasal swab, streamlined processing and clear result window.
• Affordable Access: Cost-effective visual combo test.

"Physician office labs and urgent care centers are on the front lines of respiratory illness diagnosis. With the QUICKVUE Influenza + SARS Test, we're equipping healthcare providers with a reliable, affordable and efficient tool to differentiate between COVID-19 and influenza in minutes," said Tammi Ranalli , PhD, Senior Vice President, Molecular Diagnostics and Point of Care Business Units, QuidelOrtho. "This innovation reflects QuidelOrtho's commitment to supporting healthcare professionals with cost-effective solutions that streamline clinical decisions and help manage seasonal surges in respiratory infections."

The launch of the QUICKVUE Influenza + SARS Test expands QuidelOrtho's portfolio of respiratory solutions, including the SOFIA ^™ 2 Flu + SARS Antigen FIA, by offering a visually read option alongside QuidelOrtho's instrumented version and reinforces QuidelOrtho's market leadership in point-of-care respiratory testing. The QUICKVUE Influenza + SARS Test is available in the United States through QuidelOrtho's existing distribution channels and is not intended for in-home use.

About QuidelOrtho Corporation

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

For more information, visit  www.quidelortho.com  and follow QuidelOrtho on LinkedIn, Facebook and X.

Investor Contact:

Juliet Cunningham

Vice President, Investor Relations

IR@QuidelOrtho.com

Media Contact:

D. Nikki Wheeler

Senior Director, Corporate Communications

media@QuidelOrtho.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/quidelortho-announces-availability-of-quickvue-influenza--sars-test-for-professional-use-302561981.html

SOURCE QuidelOrtho Corporation